<DOC>
	<DOCNO>NCT00783549</DOCNO>
	<brief_summary>This study first study human assess safety tolerability various dos GSK1292263 alone , take sitigliptan .</brief_summary>
	<brief_title>A Study Healthy Volunteers Single Doses Orally Administered Investigational Product Investigate Safety , Tolerability , Pharmacokinecs .</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Healthy Male female 18 55 year age A female subject eligible participate nonchildbearing potential Male subject must agree use one contraception method list protocol BMI within range 20 29.9 kg/m2 Capable give write informed consent , include compliance protocol QTcB QTcF &lt; 450msec . The subject positive prestudy drug/alcohol screen Positive urinary cotinine level history regular use tobacco nicotinecontaining product within 6 month prior screen . History regular alcohol consumption within 6 month study History sensitivity heparin heparininduced thrombocytopenia Unable unwilling abstain caffeineor xanthinecontaining product 24 hour prior dose final postdose assessment treatment level . Use illicit drug . Use alcohol 24 hour prior dose final postdose assessment treatment level . Consumption red wine , orange , grapefruit grapefruit juice 7 day prior first dose study medication collection final pharmacokinetic pharmacodynamic blood sample A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive test HIV antibody Pregnant female determine positive urine hCG test screen prior dose Lactating female Has fast triglyceride level &gt; 400mg/dL ( 4.45mmol/L ) Has anemia define hemoglobin concentration &lt; 11.0g/dL male &lt; 10.0g/dL female . CPK value high 2.5 time upper limit normal screening . Significant ECG abnormalities abnormal vital sign define History gastrointestinal hepatic condition could impact absorption investigational compound . Family history ( first second degree relative ) history hypertrophic cardiomyopathy . Family history torsade de pointes ventricular arrhythmia . Family history unexplained sudden death . Evidence early depolarization ( e.g. , WolfParkinsonWhite syndrome ) . Has clinically significant rhythm abnormality identify 24hour Screening Holter assessment . Subjects asthma history asthma The subject participate clinical trial receive investigational product within protocol define period Exposure four new chemical entity within 12 month prior first dose day Use prescription nonprescription drug , include vitamin , herbal dietary supplement within 7 day 14 day drug potential enzyme inducer 5 halflives prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation Subjects take lowdose aspirin cardiovascular prophylaxis ( 81mg less ) eligible participate study , aspirin must discontinue Screening Followup visit Where participation study would result donation blood blood product excess 500 mL within 56 day period Unwillingness inability follow procedure outline protocol . As result medical interview , physical examination , screen investigation , investigator considers subject unfit study . Subject either immediate family member participate investigator , study coordinator , employee investigator ; member staff conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>tolerability</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
</DOC>